We selected 12 genes, which have been demonstrated to be required for the enzalutamide resistance and neuroendocrine differentiation of prostate cancer, and determined whether their expression are affected by the SLC12A5/YTHDC1 complex. Here, SLC12A5 is linked to prostate carcinoma.